Work

Benefits of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) on Symptoms and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease (COPD) in the ETHOS Trial

Year: 2020

Type: conference-abstract

Source: American Journal of Respiratory and Critical Care Medicine

DOI: 10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a5073

Authors: F.J. Martinez, K.F. Rabe, G.T. Ferguson, J.A. Wedzicha, R. Trivedi, E. St Rose, S. Ballal, P. Darken, M. Aurivillius, P. Dorinsky, C. Reisner

Institutions: Weill Cornell Medicine, German Center for Lung Research, LungenClinic Grosshansdorf, Imperial College London, AstraZeneca (United States), AstraZeneca (Sweden)

Language: English

Topic: Chronic Obstructive Pulmonary Disease (COPD) Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3041511800

Cites:

Cited by: 3

Related to: 10